Acute respiratory distress syndrome (ARDS) is characterized by acute onset of diffuse bilateral pulmonary edema and severe hypoxemia not fully explained by cardiac dysfunction [1]. Primarily defined for adults, ARDS affects 10% of mechanically ventilated children in pediatric intensive care units (PICUs) [2], with a mortality rate of 20% in modern cohorts [3, 4]. ARDS is heterogeneous, with patients having distinct co-morbidities and inciting etiologies (pneumonia, non-pulmonary sepsis). This heterogeneity has contributed to negative trial results in adults and pediatrics, as therapies effective in some patients are ineffective in others [5]. Methods to reduce heterogeneity including sub-phenotyping using protein and mRNA biomarkers have been proposed for improving patient selection for future clinical trials [6]. Biomarkers have also been proposed to predict development of, accurately diagnose, and prognosticate ARDS. Biomarkers may also provide insight into ARDS pathophysiology, which remains remarkably imprecise despite 50 years of research.

Following the lead of our adult colleagues [7], pediatric ARDS has recently experienced an explosion of manuscripts describing (primarily circulating) protein biomarkers for use in prognostication and risk stratification (reviewed in [8]). These biomarkers include damage-associated molecular patterns, inflammatory proteins (interleukins, cytokines), coagulation-associated proteins, markers of endothelial damage, and a few proteins putatively representing alveolar epithelial damage. The more promising biomarkers, such as the soluble receptor for advanced glycation end-products (sRAGE) [9], angiopoietin-2 [9, 10], and thrombomodulin [11], are strongly associated with mortality and potentially relate to pathophysiology.

However, the utility of these biomarkers expressly depends upon their intended use, which is intimately related to the epidemiology of pediatric ARDS. First, most children with ARDS do not die of hypoxemia, the defining hallmark of ARDS. Multisystem organ failure and withdrawal due to poor neurologic prognoses or underlying co-morbidities are responsible for most deaths [3]. Second, mortality is much lower in pediatric ARDS, which is why it is rarely chosen as the primary outcome in trials. Rather, composites such as ventilator-free days are more common. Unfortunately, few biomarkers have been associated with ventilator duration, so their utility in prognosticating the most common outcome used in pediatric ARDS trials is unknown. These preceding two points therefore suggest that the majority of “ARDS” biomarkers published to date are not specific for ARDS; rather, they are identifying mortality risks associated with either severe inflammation or non-specific tissue damage, with little indication that they relate to a pulmonary process like ARDS. This includes markers putatively related to alveolar epithelial damage, such as sRAGE, which is primarily expressed in lung epithelial cells. However, levels of sRAGE are also associated with non-pulmonary organ failures (and mortality) in pediatric ARDS [9], consistent with the expression of sRAGE in non-pulmonary tissues, including endothelial cells. It is possible that peripheral blood is the wrong compartment to identify a biomarker specific for pediatric ARDS and that investigating the proteome of the alveolar space may be more useful. However, this logical proposal confronts the reality that bronchoalveolar lavage sampling of ARDS in children is far rarer than in adults and would require extensive resources and practice change. Thus, a biomarker specific for pediatric ARDS remains elusive, and we continue to rely on clinical criteria for diagnosis and prognostication [12].

This is not to imply that these biomarkers cannot be useful. A subtype of pediatric ARDS characterized by elevated angiopoietin-2, for example, may benefit from a treatment targeting angiopoietin signaling, an example of predictive enrichment. The prognostic utility of certain biomarkers may assist with identifying a subgroup at high risk for mortality (e.g., prognostic enrichment) and thus appropriate for trials of high-risk therapies, such as high-frequency oscillatory ventilation.
or extracorporeal support. However, what should be clear is that the existing biomarkers are not identifying pathophysiology or risk stratification specific to pediatric ARDS. Angiopoietin-2, for example, has prognostic utility in pediatric sepsis, as well [13], and does not necessarily implicate ARDS-specific pathophysiology.

This, therefore, is the central question as we see more publications on biomarkers in pediatric ARDS: how do we intend to use the biomarker? If used to predict or diagnose ARDS, then the biomarker (or, more likely, panel of biomarkers) should be more specific for ARDS than what has been published to date. If used for prognostic or predictive enrichment, then the utility of the biomarker should be tested and framed appropriately, as it still may be useful, despite lacking specificity for a pulmonary process like ARDS. If used to identify pathophysiology, then studies should be clear regarding whether they are identifying pathways specific to ARDS, or to organ failures in any inflammatory syndrome.

This is an area in which we can follow the lead of our oncology colleagues. The recent successes of “tumor-agnostic” therapies, in which therapies designed around positive biomarkers (e.g., anti-programmed cell death-1 and tropomyosin receptor kinase), rather than an anatomic or histologic cancer type, are a paradigm shift [14]. Critical care is mired in the imprecise terminology of oncology 50 years past, using syndromic terms such as “sepsis” and “ARDS.” However, critical care syndromes demonstrate significant overlap of presentation, and potentially pathophysiology, which is the exact scenario in which biomarkers can play a role more precisely defining the true pathology. We, too, can shift our paradigm, and this may point us towards the most efficient use of these biomarkers. In the near future, pediatric critical care may not be caring for children with sepsis, ARDS, traumatic brain injury, or post-cardiac arrest syndrome; rather, we may be discussing angiopoietin-dysregulated endotheliopathy, sRAGE-positive organ failures, and human-leukocyte antigen DR-deficient immunosuppression. Thus, the argument regarding how to advance the promise of precision medicine is not whether we should be better lumpers or splitters, but whether we should radically change how we view our patients.

Consent for publication
Not applicable.

Competing interests
Dr. Yehya receives institutional funding from Pfizer, outside of the scope of this manuscript.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 8 March 2019 Accepted: 15 March 2019
Published online: 25 March 2019

References
1. Force ADT, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012;307(23):2526–33.
2. Yehya N, Servaes S, Thomas NJ. Characterizing degree of lung injury in pediatric acute respiratory distress syndrome. Crit Care Med. 2015;43(5):937–46.
3. Dowell JC, Parvathaniemi K, Thomas NJ, Khermani RG, Yehya N. Epidemiology of cause of death in pediatric acute respiratory distress syndrome. Crit Care Med. 2018;46(11):1811–9.
4. Khermani RG, Smith L, Lopez-Fernandez YM, Kwok J, Morzov R, Klein MJ, Yehya N, Willson D, Kneyber MCh, Lillie J, et al. Paediatric acute respiratory distress syndrome incidence and epidemiology (PARDIE): an international, observational study. Lancet Respir Med. 2019;7(2):115–28.
5. Iwashyna TJ, Burke JF, Sussman JB, Prescott HC, Hayward RA, Angus DC. Implications of heterogeneity of treatment effect for reporting and analysis of randomized trials in critical care. Am J Respir Crit Care Med. 2015;192(9):1045–51.
6. Prescott HC, Caffee CS, Thompson BT, Angus DC, Liu VX. Toward smarter lumping and smarter splitting: rethinking strategies for sepsis and acute respiratory distress syndrome clinical trial design. Am J Respir Crit Care Med. 2016;194(2):147–55.
7. Caffee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA, Network NA. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014;2(8):611–20.
8. Orwoll BE, Sapru A. Biomarkers in pediatric ARDS: future directions. Front Pediatr. 2016;4:58.
9. Yehya N, Thomas NJ, Meyer NJ, Christie JD, Berg RA, Marquilles SS. Circulating markers of endothelial and alveolar epithelial dysfunction are associated with mortality in pediatric acute respiratory distress syndrome. Intensive Care Med. 2016;42(7):1137–45.
10. Zinter MS, Spicer A, Orwoll BD, Alkhouri M, Dvorak CC, Caffee CS, Matthay MA, Sapru A. Plasma angiopoietin-2 outperforms other markers of endothelial injury in prognosticating pediatric ARDS mortality. Am J Physiol Lung Cell Mol Physiol. 2016;310(3):L224–31.
11. Orwoll BE, Spicer AC, Zinter MS, Alkhouri MF, Khermani RG, Flori HR, Neuhaus JM, Caffee CS, Matthay MA, Sapru A. Elevated soluble thrombomodulin is associated with organ failure and mortality in children with acute respiratory distress syndrome (ARDS): a prospective observational cohort study. Crit Care. 2015;19(1):435.
12. Pediatric Acute Lung Injury Consensus Conference G. Pediatric acute respiratory distress syndrome: consensus recommendations from the Pediatric Acute Lung Injury Consensus Conference. Pediatr Crit Care Med. 2015;16(5):428–39.
13. Giuliano JS Jr, Lahni PM, Harmon K, Wong HR, Doughty LA, Cricillo JA, Zingarelli B, Suhhatme VP, Parikh SM, Wheeler DS. Admission angiopoietin levels in children with septic shock. Shock. 2007;28(6):650–4.
14. Yan L, Zhang W. Precision medicine becomes reality—tumor type-agnostic therapy. Cancer Commun (Lond). 2018;38(1):6.

Funding
NIH/NHLBI K23-HL136688 (NY). The funding body had no role in the preparation of this manuscript.

Availability of data and materials
Not applicable.

Author’s contributions
NY wrote and is responsible for the manuscript. The author read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable.